Skadden is representing OSI Pharmaceuticals Inc., which has announced a definitive merger agreement under which Astellas Pharma Inc. will acquire OSI. The boards of directors of both companies have unanimously approved the combination, which was announced on May 16. The all-cash transaction is valued at $4 billion on a fully diluted basis. Both companies are pharmaceutical manufacturers.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates